Deutsche Bank
KYMR icon

Deutsche Bank’s Kymera Therapeutics KYMR Stock Holding History

Deutsche Bank’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.65M Buy
91,882
+12,039
+15% +$953K ﹤0.01% 1146
2025
Q4 		$6.21M Buy
79,843
+7,106
+10% +$480K ﹤0.01% 1222
2025
Q3 		$4.12M Buy
72,737
+21,822
+43% +$984K ﹤0.01% 1395
2025
Q2 		$2.22M Sell
50,915
-3,092
-6% -$106K ﹤0.01% 1638
2025
Q1 		$1.48M Sell
54,007
-18,435
-25% -$672K ﹤0.01% 1947
2024
Q4 		$2.91M Buy
72,442
+28,726
+66% +$1.3M ﹤0.01% 1617
2024
Q3 		$2.07M Buy
43,716
+7,483
+21% +$330K ﹤0.01% 1717
2024
Q2 		$1.08M Sell
36,233
-5,643
-13% -$195K ﹤0.01% 1949
2024
Q1 		$1.68M Buy
41,876
+21,808
+109% +$780K ﹤0.01% 1750
2023
Q4 		$511K Buy
20,068
+184
+0.9% +$3.29K ﹤0.01% 2373
2023
Q3 		$276K Buy
19,884
+2,390
+14% +$48K ﹤0.01% 2567
2023
Q2 		$402K Sell
17,494
-7,707
-31% -$221K ﹤0.01% 2478
2023
Q1 		$747K Buy
25,201
+4,220
+20% +$136K ﹤0.01% 2274
2022
Q4 		$524K Buy
20,981
+5,005
+31% +$133K ﹤0.01% 2423
2022
Q3 		$348K Sell
15,976
-4,200
-21% -$111K ﹤0.01% 2606
2022
Q2 		$397K Sell
20,176
-13,190
-40% -$308K ﹤0.01% 2745
2022
Q1 		$1.41M Sell
33,366
-2,084
-6% -$88K ﹤0.01% 2117
2021
Q4 		$2.25M Sell
35,450
-169
-0.5% -$9.84K ﹤0.01% 1921
2021
Q3 		$2.09M Buy
35,619
+16,519
+86% +$958K ﹤0.01% 2058
2021
Q2 		$926K Buy
19,100
+12,302
+181% +$534K ﹤0.01% 2817
2021
Q1 		$264K Sell
6,798
-612
-8% -$36.8K ﹤0.01% 3478
2020
Q4 		$460K Buy
+7,410
New +$361K ﹤0.01% 2965

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Deutsche Bank's KYMR Position: Q1 2026 in Review

Deutsche Bank increased its Kymera Therapeutics (KYMR) stake by 15% in Q1 2026, buying an estimated $953K and bringing the position to 91,882 shares worth $7.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

Deutsche Bank first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Deutsche Bank held 91,882 shares of Kymera Therapeutics worth $7.65M as of Q1 2026.
  • Deutsche Bank bought 12,039 Kymera Therapeutics shares in Q1 2026, an estimated $953K.
  • Kymera Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1146 holding.
  • Deutsche Bank first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.